Singal Ashwani K, Duchini Andrea
Ashwani K Singal, Andrea Duchini, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905-0001, United States.
World J Hepatol. 2011 Aug 27;3(8):215-8. doi: 10.4254/wjh.v3.i8.215.
Acute alcoholic hepatitis (AH) is a distinct clinical entity amongst patients with chronic alcohol abuse. Patients with severe AH are at risk of dying in about 20%-25% cases despite specific treatment with corticosteroids and/or pentoxifylline. Clearly, a need for an additional more effective treatment option is unmet currently. Liver transplantation (LT), a definitive treatment option for alcoholic cirrhosis requires 6 mo abstinence. However, this rule cannot be applied to patients with AH as these patients are actively drinking prior to their presentation. Shortage of donors, ethical issues, and fear of recidivism after transplantation with less than 6 mo pre-transplant abstinence are some of the reasons behind this rule of 6 mo of abstinence and hesitancy of transplanting patients with AH. These issues are debated at length in this manuscript. Further, retrospective studies have shown that patients undergoing transplantation for alcoholic cirrhosis and having histological changes of AH have been shown to fare as well when compared to patients without these histological changes. Recently, French workers have reported a case matched prospective study showing encouraging data on the usefulness of LT for patients who are non-responders to corticosteroid and/or pentoxifylline therapy. Future studies are needed to identify patients with severe AH who are going to benefit most with LT. In the light of emerging data on the efficacy of LT in improving survival of patients with severe acute AH who do not respond to corticosteroids, the time is ripe to re-evaluate our policy of LT in patients with AH.
急性酒精性肝炎(AH)在慢性酒精滥用患者中是一种独特的临床实体。尽管使用皮质类固醇和/或己酮可可碱进行了特异性治疗,但重度AH患者仍有20%-25%的死亡风险。显然,目前尚未满足对另一种更有效治疗选择的需求。肝移植(LT)是酒精性肝硬化的确定性治疗选择,需要戒酒6个月。然而,这条规则不适用于AH患者,因为这些患者在就诊前仍在积极饮酒。供体短缺、伦理问题以及对移植前戒酒不足6个月的患者移植后复发的担忧是这条6个月戒酒规则以及对AH患者进行肝移植犹豫不决的部分原因。本文将详细讨论这些问题。此外,回顾性研究表明,与没有这些组织学改变的患者相比,因酒精性肝硬化接受移植且有AH组织学改变的患者预后同样良好。最近,法国研究人员报告了一项病例匹配的前瞻性研究,并公布了令人鼓舞的数据,表明肝移植对皮质类固醇和/或己酮可可碱治疗无反应的患者有用。需要进一步的研究来确定哪些重度AH患者将从肝移植中获益最大。鉴于肝移植在改善对皮质类固醇无反应的重度急性AH患者生存率方面的新数据,重新评估我们对AH患者肝移植的政策时机已经成熟。